Institute of Orthopaedics and Traumatology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
Department of Pharmacy, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.
Drug Des Devel Ther. 2021 Dec 2;15:4911-4924. doi: 10.2147/DDDT.S338439. eCollection 2021.
To explore the pharmacological mechanisms of Liuwei Dihuang Decoction (LWDHD) against intervertebral disc (IVD) degeneration (IVDD) via network pharmacology analysis combined with experimental validation.
First, active ingredients and related targets of LWDHD, as well as related genes of IVDD, were collected from public databases. The protein-protein interaction (PPI) network, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analyses were performed to predict the core targets and pathways of LWDHD against IVDD. Secondly, the IVDD model of mice treated with LWDHD was selected to validate the major targets predicted by network pharmacology.
By searching the intersection of the active ingredient targets and IVDD targets, a total of 110 targets matched the related targets of 30 active ingredients in LWDHD and IVDD were retrieved. PPI network analysis indicated that 17 targets, including Caspase-3, IL-1β, P53, etc., were hub targets. GO and KEGG enrichment analyses showed that the apoptosis pathway was enriched by multiple targets and served as the target for in vivo experimental study validation. The results of animal experiments revealed that LWDHD administration not only restored the decrease in disc height and abnormal degradation of matrix metabolism in IVDD mice but also reversed the high expression of Bax, Caspase-3, IL-1β, P53, and low expression of Bcl-2, thereby inhibiting the apoptosis of IVD tissue and ameliorating the progression of IVDD.
Using a comprehensive network pharmacology approach, our findings predicted the active ingredients and potential targets of LWDHD intervention for IVDD, and some major target proteins involved in the predictive signaling pathway were validated experimentally, which gave us a new understanding of the pharmacological mechanism of LWDHD in treating IVDD at the comprehensive level.
通过网络药理学分析结合实验验证,探讨六味地黄汤(LWDHD)防治椎间盘退变(IVDD)的药理机制。
首先,从公共数据库中收集 LWDHD 的活性成分及相关靶点和 IVDD 的相关基因,进行蛋白质-蛋白质相互作用(PPI)网络、基因本体(GO)和京都基因与基因组百科全书(KEGG)功能富集分析,预测 LWDHD 防治 IVDD 的核心靶点和通路。其次,选择 LWDHD 治疗 IVDD 模型的小鼠,验证网络药理学预测的主要靶点。
通过搜索活性成分靶点与 IVDD 靶点的交集,共得到 30 种 LWDHD 活性成分相关靶点与 IVDD 相关靶点匹配的 110 个靶点。PPI 网络分析表明,Caspase-3、IL-1β、P53 等 17 个靶点是枢纽靶点。GO 和 KEGG 富集分析表明,多个靶点富集到凋亡通路,作为体内实验研究验证的靶点。动物实验结果表明,LWDHD 给药不仅恢复了 IVDD 小鼠椎间盘高度降低和基质代谢异常降解,还逆转了 Bax、Caspase-3、IL-1β、P53 的高表达和 Bcl-2 的低表达,从而抑制了 IVD 组织的凋亡,改善了 IVDD 的进展。
采用综合网络药理学方法,预测了 LWDHD 干预 IVDD 的活性成分和潜在靶点,实验验证了预测信号通路中一些主要的靶蛋白,从综合水平上为我们提供了理解 LWDHD 治疗 IVDD 的药理机制的新认识。